Clinical Trial – TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma – Renal Cell Carcinoma

Dana-Farber Cancer Institute is running a clinical trial to test a drug called TAK-228 to treat Renal Cell Carcinoma. This research study is investigating a drug as a possible treatment for metastatic renal cell carcinoma.

The drug is TAK-228.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Actual Study Start Date : June 29, 2017
Estimated Primary Completion Date : August 25, 2020
Estimated Study Completion Date : August 25, 2024

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.